Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 9/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.48 |
| ▸ | ADK | P55263 | 1/20 | 0.45 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19837846 | 0.87 | ADORA3 (0.70) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL19843967 | 0.84 | ADORA3 (0.65) | ADORA3LMNATP53ADK | |
| SCHEMBL6671390 | 0.78 | ADORA3 (0.67) | ADORA3ADORA1ADORA2AADKADORA2B | |
| SCHEMBL18172261 | 0.77 | ADORA3 (0.72) | ADORA3ADORA2AADORA2B | |
| SCHEMBL14408092 | 0.77 | ADORA3 (0.70) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL19843955 | 0.77 | ADORA3 (0.70) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL13992685 | 0.77 | ADORA3 (0.53) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL13788578 | 0.77 | ADORA3 (0.53) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL14264202 | 0.77 | ADORA3 (0.76) | ADORA3LMNATP53ADORA1ADORA2A | |
| SCHEMBL19837865 | 0.76 | ADORA3 (0.69) | ADORA3ADORA1ADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180037601-A1 | Nucleoside-Based Anti-Bacterial and Anti-Protozoan Drugs | UTI LIMITED PARTNERSHIP (CA) | 2018-02-08 | — | — | US | disclosed |
| US-20180037601-A1 | Nucleoside-Based Anti-Bacterial and Anti-Protozoan Drugs | UTI LIMITED PARTNERSHIP (CA) | 2018-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180037601-A1 | Nucleoside-Based Anti-Bacterial and Anti-Protozoan Drugs | PNP, NUDT1, SLC29A1 | ADORA3 78/4885LMNA 1674/4885TP53 4696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.